The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education. Read more
In reference to: Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431. Checkpoint blockade with PD-1 or PD-L1 […] Read more
Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021. “To put […] Read more
In 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic […] Read more
The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung […] Read more
ILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction […] Read more
In September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung […] Read more
As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with […] Read more
In Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, […] Read more
IN REFERENCE TO: Khorrami M, Jain P, Bera K, et al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019;135:1-9. Read more
Although some resist its gravitational pull, social media and especially Twitter are becoming an increasingly valuable tool in academic and community-based cancer care, with thoracic oncology helping set the pace […] Read more